[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590073":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":33,"locations":41,"responsibleParty":55,"collaborators":23,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":23,"enrollmentInfo":70,"targetDuration":23,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":23,"overallStatus":44,"whyStopped":23,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Erlangen-Nürnberg Medical School","OTHER",[8,14],{"label":9,"type":6,"description":10,"interventionNames":11},"Case group (subjects with known pre-existing or current cancer diagnosis)","The case group will consist of subjects with a known pre-existing or current cancer diagnosis, including breast cancer, lung cancer, colorectal cancer or gynecologic cancer",[12,13],"Other: Biomaterial collection","Other: BayPass mobile application",{"label":15,"type":6,"description":16,"interventionNames":17},"Control group (healthy subjects)","The control group will consist of healthy subjects with no history of cancer",[12,13],[19,24],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"Biomaterial collection","All subjects will be asked to provide biomaterial (blood or saliva) for bio marker screening and analysis. Additional biomaterial (breath, urin, stool) is optional.",[9,15],null,{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"BayPass mobile application","All subjects will be asked to use the study-specific mobile application \"BayPass\" to complete questionnaires and provide results from screening examinations over a course of 12 months.",[9,15],[29],{"name":30,"affiliation":31,"role":32},"Matthias W. Beckmann, Prof. Dr. med.","Head of Department of Obstetrics and Gynecology","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":23,"email":38},"Peter A. Fasching, Prof. Dr. med.","CONTACT","+49 9131 85 33572","fk-digionko@uk-erlangen.de",{"name":40,"role":36,"phone":23,"phoneExt":23,"email":38},"Hanna Hübner, PD Dr. rer. nat.",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":23,"country":47,"countryCode":48,"cosmosGeoPoint":23,"geoPoint":23,"contacts":49},"DigiOnko Präventionsmobil","RECRUITING","Please Refer to Project Homepage For Details (see Link Below)","Bavaria","Germany","DE",[50,53],{"name":51,"role":36,"phone":52,"phoneExt":23,"email":38},"Hanna Hübner, PD Dr. rer. nat. med. habil.","+49 9131 8533572",{"name":35,"role":54,"phone":23,"phoneExt":23,"email":23},"PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":58,"oldNameTitle":23,"oldOrganization":23},"Peter A. Fasching","Prof. Dr. med.","University Hospital Erlangen","100590073","predicting-cancer-risk-with-digital-and-molecular-markers-100590073",false,"NCT06962670","Predicting Cancer Risk With Digital and Molecular Markers","Digital and Molecular Detection of Markers for Disease Risk Prediction, Improvement of Diagnostic Detection Accuracy and Implementation for Preventive Measures of Cancer - A Combined Case-control and Cohort Study","PräDigt","Inclusion Criteria:\n\n1. Biological adult (at least 18 years old) women\n2. Written informed consent for study participation and processing of personal data\n3. Own smartphone that can run the BayPass mobile application and willingness to use said smartphone for study purposes\n\n   Additional inclusion criterion for case group:\n4. Pre-existing or current diagnosis of at least one of the following oncological diseases: breast cancer, lung cancer, colorectal cancer, gynecologic cancer (incl. ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, vaginal cancer and vulvar cancer)\n\nExclusion Criteria:\n\n1. Known infection with HIV (Human Immunodeficiency Virus), HepA (Hepatitis A), HepB (Hepatitis B), HepC (Hepatitis C) or active SARS-CoV2 (Severe acute respiratory syndrome coronavirus type 2) infection\n2. Acute severe or potentially life-threatening illness, except those specified in inclusion criterion #4",true,"FEMALE","18 Years",{"count":71,"type":72},1250,"ESTIMATED","INTERVENTIONAL",[75],"NA","The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and healthy individuals. If characteristic differences are identified, e.g. in biomarkers, life style or family history, this may indicate a person's increased risk of developing cancer.",[78,79,80,81],"Breast Cancer","Lung Cancer","Colorectal Cancer","Gynecologic Cancer","2025-04-29",{"date":84,"type":85},"2025-05-08","ACTUAL",{"date":87,"type":85},"2024-09-14",{"date":89,"type":72},"2025-12",{"name":5,"class":6},1]